business
necolas00073
1532218022drugrevolutiongraceblankspreadsheet.xlsNet Income
| Forecasted Income Statement ($000's) |
| Joint-Venture |
| Market Penetration |
| U.S. Market prescriptions filled |
| Eligibility |
| Total Eligible U.S. prescriptions |
| European Market prescriptions filled |
| Eligibility |
| Total Eligible European Prescriptions |
| Total Customer Base Both Markets |
| Total Revenues($000) |
| Variable Costs (000's) |
| Fixed Expenses (000's) |
| Depreciation (000's) |
| EBIT (000's) |
| Tax (@30%)* |
| Net Income (000's) |
| * Note: Assume there is no tax effect if EBIT is negative. |
Free Cash Flow
| Drug Revolution/Grace Pharm Joint-Venture | |||
| Forecast of Cash Flows (000's) | |||
| Net Income | |||
| Add back depreciation | |||
| Net Operating Cash Flow | |||
| Net Working Capital | |||
| Change in NWC | |||
| Recovery of NWC | |||
| Total Change in NWC | |||
| Capital Spending | |||
| Initial Outlay | |||
| Free Cash Flow | |||
| JV | Drug Revolution | Grace Pharm | |
| Enterprise Value (000's) | |||
| Drug Revolution Investment | |||
| Drug Revolution NPV |
